Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Urology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/s1470-2045(19)30569-8

License

CC-BY

Other Formats

PDF